Press Releases

07/08/2015

SeraCare Life Sciences’ Precision Medicine Unit Launches New Product to Ensure Accuracy of NGS Assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.

06/26/2015

SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.